Professoriate Staff

Professor Feng, Yibin
Professor, Acting Director
School of Chinese Medicine,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong
  • School of Chinese Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong
  • (852) 3917 6476
  • (852) 2872 5476
  • yfeng@hku.hk
SPOKEN LANGUAGES

Mandarin, English, Cantonese and Japanese

WRITTEN LANGUAGES

Mandarin, English, Cantonese and Japanese

AREAS OF EXPERTISE

Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines; Cancer, metabolic diseases, liver and kidney diseases; Chinese Medicine education

ACADEMIC QULIFICATION

Med, MMed Course, PhD

CURRENT PROFESSIONAL SERVICES

- Member of the Chinese Medicine Council of Hong Kong;

- Member of Chinese Medicines in Hospital Authority of Hong Kong;

- Panel-member of Chinese Medicine (Pharmaceutical) Committee in Hospital Authority of Hong Kong;

- Panel-member of Use of Proprietary Chinese Medicine Steering Committee in Hospital Authority of Hong Kong;

- Panel-member of Chinese medicine experts for registration of proprietary Chinese medicines in the Chinese Medicine Council of Hong Kong;

- Organizing Committee member for International Conference & Exhibition of the Modernization of Chinese Medicine & Health Products (ICMCM) (Annual Conference, 2005-present);

- Joint-Chairman for International Conference & Exhibition of the Modernization of Chinese Medicine & Health Products (ICMCM) (2013, 2018, 2019, Hong Kong);

- Convenor of academic advisory board (2007) and organizing committee for HK-Macao postgraduate Symposium on Chinese Medicine (Annual Symposium2005-present, Hong Kong)

- Executive Chairman for The third international symposium and the third national annual conference on dietotherapy and Chinese medicated diet (2012, Hong Kong)

- External reviewer for Bachelor of Science (Hons) Chinese Medicine Program at International Medical University, Malaysia (2012-present)

- WHO observer for Regional Launching and Workshop on Implementing the Regional Strategy for Traditional Medicine in the Western Pacific (2011-2020), 7-8 May 2012, Hong Kong SAR, China

- WHO Expert for The second WHO consultation on quality control of herbal medicines Hong Kong SAR, China, 17-19 November 2014; 4-6 September 2017

- Organizing committee member for Traditional & Alternative Medicine 2016, Amsterdam, Netherlands, September 14-16, 2016

- Organizing committee Chairman for Pong Ding Yueng International Symposium on Chinese Medicine, Hong Kong, 1-3 December 2017

- Standing member of Hong Kong Registered Chinese Medicine Practitioner Association.

- Editors and reviewers for over seventy international journals in Chinese medicine, integrated medicine, complementary and alternative medicine, as well as biomedicine etc.

WORK EXPERIENCE
Sep., 2020 - Present Acting Director, Professor, Supervisor of PhD Candidates and Post-Doctorate Fellows, School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner; Master of Chinese Medicine Programme Stream Co-ordinator (Oncology), School of Chinese Medicine, The University of Hong Kong
February, 2020 – Sep., 2020 Acting Director, Associate Professor, Supervisor of PhD Candidates and Post-Doctorate Fellows, School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner; Master of Chinese Medicine Programme Stream Co-ordinator (Oncology), School of Chinese Medicine, The University of Hong Kong
Oct. 2017-Nov. 2017 Served as Visiting scientist supported by HKU oversea scholarship in Department of Pharmacology, Yale University School of Medicine, USA
2014 - 2020 Associate Professor, Associate Director (Education), School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner
2011 - 2014 Associate Professor, Assistant Director (Education), School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner
2010 - 2011 Assistant Professor, Assistant Director (Education), School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner
2004 - 2009 Assistant Professor, Bachelor of Chinese Medicine (BChinMed in full- time) Programme Co-Ordinator, School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Hong Kong Registered Chinese Medicine Practitioner
2002 - 2004 Chinese Medicine Assistant Professor, School of Chinese Medicine, The University of Hong Kong, Hong Kong; and Limited Registered Chinese Medicine Practitioner in Hong Kong
2000 - 2002 CM Assistant Professor, Division of Chinese Medicine, SPACE, The University of Hong Kong, Hong Kong; and Limited Registered Chinese Medicine Practitioner in Hong Kong.
1997 - 1999 Post-Doctoral research fellow, Department of Laboratory Technology and Department of Medicine II, Hokkaido University School of Medicine, Japan
1991 - 1993 Visiting Scientist, Department of Pharmacology, Faculty of Pharmacy, Meijio University, Japan
1987 - 1991 Lecturer, Department of Chinese Materia Medica, Yunnan University of Traditional Chinese Medicine, China
1983 - 1985 Physician, Departments of Infection, and Chinese Medicine, Dehong People’s Hospital, Yunnan, China.
RESEARCH INTEREST AND ACHIEVEMENT

Dr Yibin Feng is currently the Professor (since September2020), Acting Director (Since February 2020) in School of Chinese Medicine, the University of Hong Kong. Dr. Feng awarded Bachelor degree in Chinese Medicine from Yunnan University of Chinese medicine in China. He awarded his PhD degree in molecular medicine from Hokkaido University School of Medicine in Japan. He finished postdoctoral research in molecular pharmacology, Hokkaido University in 1999. In his early carrier years, Dr. Feng got various scholarships and research funds from Chinese Government, Japanese Government, Sumitomo social welfare consortium, FUJISAWA Pharmaceutical Limited Incorporation and TSUMURA KAMPO Pharmaceutical Limited Incorporation etc. His major research areas and research topics are Standardization and quality control of Chinese Medicines, Pharmacological screening and safety evaluation of Chinese Medicines; and Pharmacological action and its mechanism of Chinese Medicines as well Chinese medicine education. Recent years, as a PhD supervisor and principal investigator, his research was supported by grants from the Hong Kong Government (RGC, ITF, HMRF,HKCMDF), donations (such as Pong Ding Yueng Endowment Fund for Education & Research in Chinese-Western Medicine, Wong’s Donation for molecular cancer research in Chinese medicines, the Gaia Family Trust, Hong Kong Government-Matching funding), Hong Kong Hospital Authority’s funding for Chinese Medicine, and various industry contract research funding etc. As PI, awarded various grants over 23 million HK$ from 2004-2020. As Co-I,awarded over 20 million HK$ from 2004-2020.
Being an expert in the study of Chinese Materia Medica, Pharmacology and Toxicology of Chinese medicines, Dr. Feng’s research is focused on clinical study and experimental study for cancer and metabolic diseases by using recently developed techniques in OMICS, pharmacology, immunology and Evidence-based Medicine. He also commits to do substitute research for some endangered species used in Chinese Medicine and Chinese medicine education. He has published over 400 publications in English (142), Japanese and Chinese in his research areas. All these publications can be categorized to be top 5-10 journals and quality one journals in his research field of Chinese medicine and related fields. His research outputs have great impact on academic field, for example, For example, three of his papers, published in Autophage (namely Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)), International Journal of Molecular Sciences (IJMS, namely The Role of Oxidative Stress and Antioxidants in Liver Diseases), and Journal of Ethnopharmacology (JEP, namely Berberine and Coptidis Rhizoma as Novel Antineoplastic Agents: A Review of Traditional Use and Biomedical Investigations) were so far cited 6876, 739 and 478 respectively, as marked by Google scholar, open a new hot topic on coptis in the world and make his research always stand on top level in this field of international arena. His research on coptis and bear bile also got great attention in academia and society, for example, various media in Hong Kong, Mainland China, Taiwan and Oversea in 2008 have reported this research, and at an international conference in London in August 2010, he was invited by BBC studio for interview, he was reported by HKU bulletin as cover story in June 2013 about his research story in bear bile and one of his paper published in Journal of Ethnobiology and Ethnomedicine (Bear bile: dilemma of traditional medicinal use and animal protection) in 2009 was identified as highly accessed paper over 38000 accesses by March, 2020 on the journal website, etc.. In addition to publish papers in my research area in journals of Chinese medicine and integrative medicine, I also published high impact factor papers on Chinese herbal medicine in other reputable journals (Q1 journals in related categories), such as Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (IF5.089), BBA-Molecular Cell Research (IF 5.297), BBA- Gene Regulatory Mechanisms (IF5.440), Cellular Physiology and Biochemistry (5.50), Cancers (IF6.162), Cell death & Disease (IF6.304), British Journal of Pharmacology (IF7.730), Cancer Letters (IF7.360), Theranostics (IF 8.85), Molecular Cancer (IF15.320), Science Advances (IF13.116) etc. He has been listed as one of HKU scientists in the world’s Top 1% by Clarivate Analytics (previously Thomason Reuters, Essential Science Indicators) in 2017, 2018, 2019 and 2020. He was as lead guest editor for special issues of liver diseases for academic journals in 2011, 2016 and 2020, such as Chinese Medicine, Evidence-Based Complementary and Alternative medicine, Frontiers in Pharmacology etc.

TEACHING SUBJECTS

He has taught subjects such as Chinese Materia Medica, Pharmacology of Chinese Medicines, Toxicology of Chinese Medicines, Chinese Internal Medicine and Pharmacology. Recently, he is responsible for teaching Chinese Materia Medica, Pharmacology and toxicology of Chinese medicines, Oncology of Chinese Medicines and research methodology in Chinese medicine.

CLINICAL SERVICES

Cancer, diabetes, obesity, liver diseases and renal diseases etc.

ACADEMIC INTERNATIONAL PROFESSIONAL SERVICE

Highly active in international communities of Chinese Medicine, Ethnopharmacology, complementary and alternative medicine as well as life science, serving as editors or reviewers for the following international journals:

Editorial Board Members (over ten journals): (1) Evidence-Based Complementary and Alternative Medicine (eCAM) (2) Integrative Cancer Therapy (3) Chinese Medicine (5) Journal of Bioequivalence & Bioavailability (6) ISRN Hepatology (7) Open Journal of Apoptosis (8) UC Alternative Medicine (9) International Journal of Cancer & Diagnosis (IJCRD) (10) Current Analysis in Oncology (11) BMC Complementary Medicine and Therapies, etc. 2 Guest Associate Editor for Frontiers in Oncology and Frontiers in Pharmacology in 2020.

Reviewers (over sixty journals): Evidence-Based Complementary and Alternative Medicine (IF 2.064), Chinese Journal of Integrative Medicine (IF 1.059), Journal of Alternative and Complementary Medicine (IF1.864), Molecular and Cellular Biochemistry (IF3.659), BMC Complementary Medicine and Therapies (IF 2.833), Molecules (IF 3.267), Journal of Agricultural and Food Chemistry (IF3.412), Planta Medica (IF 2.339), Free Radical Research (IF3.188), International Journal of Molecular Sciences (IF4.556), Phytomedicine (IF4.268), Journal of Ethnopharmacology (IF3.690), American Journal of Chinese Medicine (3.682), Bioorganic & Medicinal Chemistry (IF3.07), Frontiers in Pharmacology (IF4.225), Journal of Ginseng Research (IF 5.487), Oxidative Medicine and Cellular Longevity (IF 5.103), Molecular Oncology (IF 6.574), Clinical and Translational Medicine (IF7.919), Expert Opinion on Therapeutic Targets (IF5.139), BBA-Molecular Cell Research (IF 5.538), Free Radical Biology and Medicine (6.170), Cancers (IF6.162), Clinical and Translational Medicine (IF7.919), Gut Microbes (IF8.640), Theranostics (IF8.85), Molecular Cancer (IF15.320), Advanced Science (15.804), Signal Transduction and Targeted Therapy (IF 13.496) etc..

SELECTED PUBLICATIONS
SELECTED PUBLICATIONS (*CORRESPONDING AUTHOR)
  1. Xu Y, Wang N, Tan HY, Li S, Zhang C, Zhang ZJ, Feng Y*. Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity. Theranostics, 2020,accepted for application. (IF 8.85, 5-year IF9.01).
  2. Lu Y, Chan YT, Tan HY, Li S, Wang N*, Feng Y*. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Molecular Cancer. 2020 Apr 27;19(1):79. doi: 10.1186/s12943-020-01197-3. (IF: 15.320).
  3. Wang N, Tan HY, Li S, Wang D, Xu Y, Zhang C, Wen X, Che CM, Feng Y*. SBP2 Deficiency in Adipose Tissue Macrophages Drives Insulin Resistance in Obesity. Science Advances 2019 Aug 14; 5(8):eaav0198. doi: 10.1126/sciadv.aav0198. eCollection 2019 Aug. (IF 13.116).
  4. Tan HY, Wang N, Lam W, Guo W, Feng Y*, Cheng YC*. Targeting tumour microenvironment by tyrosine kinase inhibitor. Molecular Cancer. 2018 Feb 19; 17(1):43. doi: 10.1186/s12943-018-0800-6. (IF 15.320).
  5. Zhang C, Wang N, Tan HY, Guo W, Chen F, Zhong Z, Man K, Tsao SW, Lao LX, Feng Y*. Direct inhibition of TLR4/MyD88 pathway by geniposide suppresses HIF1α-independent VEGF expression and hepatocellular carcinoma angiogenesis. British Journal of Pharmacology 2020 Mar 6. doi: 10.1111/bph.15046. [Epub ahead of print]. (IF 7.730, Q1 in Pharmacy and Pharmacology, 9/268).
  6. Wang N, Zhu M, Tsao SW, Man K, Zhang ZJ, Feng Y*. MiR-23a-mediated Inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. Molecular Cancer 2013 Oct 8; 12(1):119. (IF 15.320).
  7. Wang N, Pan W, Zhu M, Zhang M, Hao X, Liang G, Feng Y*. Fangchinoline induces autophagic cell death via p53/sestrin2/AMPK signaling in human hepatocellular carcinoma cells. British Journal of Pharmacology 2011;164(2b):731-742. (IF 7.730).
  8. Wang N, Tan HY, Li S, Feng Y*. Atg9b Deficiency Suppresses Autophagy and Potentiates Endoplasmic Reticulum Stress-Associated Hepatocyte Apoptosis in Hepatocarcinogenesis. Theranostics 2017 Jun 2; 7(8):2325-2338. (IF 8.85, 5-year IF9.01).
  9. Tan HY, Wang N, Man K, Tsao SW, Che CM, Feng Y*. Autophagy-induced RelB/p52 activation mediates tumor associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin. Cell Death and Disease (2015) 6, e; doi:10.1038/cddis.2015.271 (IF 5.959, 5-year IF 6.304).
  10. Tan HY, Ho VWT, Chan YT, Zhang C, Wang N, Xia W, Feng Y*. Combination of Gentiana rhodantha and Gerbera anandria in the BL02 formula is therapeutic in non-small cell lung cancer acting via Rap1/cdc42 Signaling: a Transcriptomics/ Bio-informatics biological validation approach. Pharmacological Research 2019 Aug 26:104415. doi: 10.1016/j.phrs.2019.104415. (IF 5.893, 5-year IF5.578)
  11. Tsang CM, Cheung KCP, Cheung YC, Man K, Lui VWY, Tsao SW, Feng Y*. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1852 (3), 541-551. (IF 5.108, 5-year IF 5.964).
  12. Wang N, Zhang C, Xu Y, Li S, Tan HY, Wang D, Xia W, Feng Y*. OMICs approaches-assisted identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL in diabetic retinopathy. Cell Communication and Signaling 2019 Jul 22;17(1):81. doi: 10.1186/s12964-019-0396-5. (IF 5.111, 5-year IF 4.603)
  13. Tan HY, Wang N, Chan YD, Zhang C, Guo W, Chen F, Zhong ZF, Li S, Feng Y*. ID1 overexpression increases gefitinib sensitivity in non-small cell lung cancer by activating RIP3/MLKL-dependent necroptosis. Cancer Letters, 2020, in press. (IF 7.360, 5-year IF 6.260).
  14. Klionsky DJ*,…Feng Y, …et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016 Jan 2; 12(1):1-222. (IF 11.100, and the 5-Year IF11.815).
  15. Li S, Tan HY, Wang N, Zhang ZJ, Lao L, Wong CW, Feng Y*. The role of oxidative stress and antioxidants in liver diseases. International journal of molecular sciences 2015, 16 (11), 26087-26124 (IF 4.181, 5-Year IF 4.331)
  16. Tang J, Feng Y*, Tsao S, Wang N, Curtain R, Wang Y. Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. Journal of Ethnopharmacology 2009, 126:5-17. (IF 3.690, 5-year IF 3.671)
  17. Wang N, Feng Y*, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. Journal of cellular biochemistry 2010, 111(6):1426-36. (IF 3.448, 5-year IF 3.342)
  18. Tan HY, Wang N, Li S, Hong M, Wang X, Feng Y*. The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases. Oxidative medicine and cellular longevity 2016, 16pages, https://doi.org/10.1155/2016/2795090. (IF 5.076)
  19. Jodo S, Kobayashi S*, Kayagaki N, Ogura N, Feng Y, Amasaki Y, Fujisaku A, Azuma M, Yagita H, Okumura K, Koike T. Serum levels of soluble Fas/APO‐1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clinical & Experimental Immunology 1997, 107:89-95. (IF 3.711, 5-year IF 3.516).
  20. Feng Y*, Siu K, Wang N, Ng KM, Tsao SW, Nagamatsu T, Tong Y. Bear bile: dilemma of traditional medicinal use and animal protection. Journal of Ethnobiology and Ethnomedicine 2009, 5 (1), 2. (IF 2.273, 5-year IF 3.06).
  21. Ye XS, Feng Y*, Tong Y, Ng KM, Tsao SW, Lau George KK, Sze CW, Zhang YB, Tang J, Shen JG, Kobayashi S. Hepatoprotective effects of Coptidis Rhizoma aqueous extract on carbon tetrachloride-induced acute liver hepatotoxicity in rats. Journal of Ethnopharmacology 2009, 124:130–136.
  22. Tsang CM+, Lau Echo PW+, Di K, Cheung PY, Hau PM, Ching YP, Wong YW, Cheung Annie LM, Wan Thomas SK, Tong Y, Tsao SW* and Feng Y*. Berberine inhibits RhoGTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. International Journal of Molecular Medicine 2009; 24:131-138. (IF 3.098, 5-year IF 3.107).
  23. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y*. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects. International journal of molecular sciences 16 (12), 28705-28745. (IF 4.556, 5-Year IF 4.331).
  24. Li S, Hong M, Tan HY, Wang N, Feng Y*. Insights into the role and interdependence of oxidative stress and inflammation in liver diseases. Oxidative medicine and cellular longevity 2016, 2016:4234061. doi: 10.1155/2016/4234061. (IF 5.076, 5-year IF 4.392).
  25. Feng Y*, Wang N, Ye X, Li H, Feng Y, Cheung F, Nagamatsu T. Hepatoprotective effect and its possible mechanism of Coptidis rhizoma aqueous extract on carbon tetrachloride-induced chronic liver hepatotoxicity in rats. Journal of Ethnopharmacology 2011,138: 683-90.
  26. Wang N, Zhu M, Wang X, Tan HY, Tsao SW, Feng Y*. Berberine-induced tumor suppressor p53 up-regulation gets involved in the regulatory network of MIR-23a in hepatocellular carcinoma. Biochim Biophys Acta (BBA) - Gene Regulatory Mechanisms. 2014 Sep; 1839(9):849-57 (IF 4.599, 5-year IF 4.932)
  27. Wang N, Feng Y*, Zhu M, Siu FM, Ng KM, Che CM*. A Novel Mechanism of XIAP Degradation Induced by Timosaponin AIII in Hepatocellular Carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2013 Jul 29;1833(12):2890-2899. 1. (IF 4.739, 5-year IF 5.281).
  28. Wang N, Feng Y*, Tan HY, Cheung F, Hong M, Lao L, Nagamatsu T. Inhibition of Eukaryotic Elongation Factor-2 Confers to Tumor Suppression by a Herbal Formulation Huanglian-Jiedu Decoction in Human Hepatocellular Carcinoma. Journal of Ethnopharmacology 2015, 164:309-318 (IF 3.690, 5-year IF 3.908)
  29. Xu Q*, Feng Y, Duez P, Hendry BM, Hylands PJ. The hunt for anti-fibrotic and pro-fibrotic botanicals. The Art and Science of Traditional Medicine Part 1: TCM Today – A Case for Integration, Science 2014;346 (6216 Suppl), S19-S20.
  30. Hong M, Wang N, Tan HY, Tsao SW, Feng Y*. MicroRNAs and Chinese medicinal herbs: new possibility in cancer therapy. Cancers 2015, 7 (3):1643-1657. (IF 6.162).
  31. Li S, Wang N, Tan HY, Hong M, Yuen MF, Li H, Feng Y*. Expansion of Granulocytic- Myeloid-derived Suppressor Cells in Response to Ethanol-Induced Acute Liver Damage. Frontiers in Immunology 2018; 9:1524. (IF 5.082, 5-year IF 5.789).
  32. Qu Y, Dou B, Tan HY, Feng Y*, Wang N*, Wang D*. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Molecular Cancer 2019 Mar 30; 18(1):69. doi: 10.1186/s12943-019-0992-4. (IF15.320).
SELECTED BOOKS AND CHAPTERS IN BOOKS (* CORRESPONDING AUTHOR)
  1. Xu HX, Zhu GF, Feng Y, Editor-in-Chief. Anticancer Chinese Medicines: Origen, chemistry, pharmacology and clinical application. Shanghai: Science Publisher. 2018, ISBN 978-7-5478-4080-1/R 1657, pp884. (In Chinese).
  2. Chen Chang-xun (Editor in Chief). Editorial board: Cao HY, Chen LY, Chen YF, Fang XY, Feng Y, Gu WL, Gu Y, Hua YQ, Huang LL, Nie Hong, Qu F, Shen YH, Solos L, Wang B, Wang J, Wang N, Wang XB, Wang YY, Xu HB, Yu S, Zhang JX. Pharmacology of Chinese Materia Medica. National “Thirteenth Five-Year_Plan” Inovative Textbooks for higher education in Chinese Medicine. China Press of Traditional Chinese Medicine. Beijing. Pp267 (in English).
  3. Chen Dexing, Wen xiapin (Editor in Chief), Editorial board: Chen BZ, Chen DX, Du GL, Fan Y, Feng Y, Hu FL, Hua HM, Jia P, Ni C, Nian L, Ruan SB, Wang F, Wang JN, Wen XP, Xin ZP, Xu XD, Yu Y, Yun XL. National Textbook for Chinese Medicine Prescription. Qinghua University Press, 1th edition, 2013. Beijing, China. pp394 (in Chinese).
  4. Alan Worsley, Feng Y, Wang N, Ho Faith, Yu Edwin, Rose Mak. Use of Herbs in Chinese and Western Medicine. Hong Kong Museum of Medical Sciences Society. 1th edition in Bilingual in Chinese and English, 2013. Hong Kong, China. pp67 (in Bilingual).
  5. Xie Mengzhou (Editor in Chief). Editorial board: Shang YQ, Yi W, Zhou J, Wu ZZ, Nie H, Shi LP, Tian SL, Feng Y, Sun ZM, Li HT, Zhang B, Lin Y, Jin H, Zhou Y, Zhao XW, Guo T, Liang XW, Xie XJ, Tai X, Sun GX. National Textbook for diet therapy. Zhong Guo Zhong Yi Yao Chu Ban She (China Chinese medicine and Chinese medicines publisher), 2nd edition, 2013. Beijing, China. pp387. (in Chinese)
  6. Feng YG, Wang N, Chueng F, Zhu M, Li H, Feng Y*. Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicines. Chapter in Biomedical Engineering, Trends, Research and Technologies (pp331-362). ISBN 978-953-307-514-3. 2011, pp644. (English).
  7. Feng Y, Chen XM, Wang N and Shen JG*. Current Progress on Medicinal Plants and their Biological Properties in Contemporary China. Chapter in Recent Progress in Medicinal Plants Vol. 28: Ethnomedicine: Source & Mechanism-II. Studium Press LLC, USA. 2010, pp491-546. (English).
  8. Tong Y and Feng Y. Assessments in the Bachelor of Chinese Medicine (BChinMed) Programme. Chapter in The assessment of the University of Hong Kong. 2009, pp51-58. Published by Institute of Medical and Health Sciences Education, Li Ka Shing Faculty of Medicine, The University of Hong Kong. (English).
  9. Feng Y, Editor-in-chief. Editorial board: Liu KJ, Wang J, Shen JG, Zhang YB, Rong JH, Tong Y, Chan KS and Wong Albert B. Basic and Clinical Toxicology of Chinese Medicines (around 460,000 words). Commercial Press (HK) Ltd. 2009. (Chinese).
  10. Yang GQ, Wu ZB, Zhang DN, Jin JM, Feng Y. A study on the prescriptions in “Herbal medicines in Yunnan”. Published by Science and Technology of Yunnan Press,1993 (ISBN7-5416-0473- 9/R.86).pp.1-319. (in Chinese).